Effectiveness and safety of liposomal amphotericin b for visceral leishmaniasis under routine program conditions in Bihar, India

American Journal of Tropical Medicine and Hygiene

Volumn 83, Issue 2, 2010, Pages 357-364

  Sinha, Prabhat K ^a   Roddy, Paul ^b   Palma, Pedro Pablo ^b   Kociejowski, Alice ^b   Lima, María Angeles ^b   Das, Vidya Nand Rabi ^a   Gupta, Jitendra ^b   Kumar, Nawin ^a   Mitra, Gaurab ^b   Saint Sauveur, Jean François ^b   Seena, Siju ^b   Balasegaram, Manica ^c   Parreño, Fernando ^d   Pandey, Krishna ^a  

^a INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

^c Drugs for Neglected Diseases Initiative   (Switzerland)

^d Centre d'Atenció Primária Florida Nord   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ADOLESCENT; ADULT; ARTICLE; BACKACHE; CHILD; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HEPATOMEGALY; HUMAN; INDIA; LEISHMANIA; LIP SWELLING; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; RASH; SWELLING; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VISCERAL LEISHMANIASIS;

ADOLESCENT; ADULT; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INDIA; LEISHMANIASIS, VISCERAL; LIPOSOMES; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 77955591768     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2010.10-0156     Document Type: Article

References (34)

1. WHO, 2009. Communicable Diseases, Kala-Azar status in SEA Region. Available at: http://www.searo.who.int/en/section10/section2163-11668.htm. Accessed December 16, 2009.
2. Desjeux P, 2004. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27: 305-318.
3. Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S, 2005. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 5: 763-774.
4. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW, 2000. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 3I: 1104-1107.
5. Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, Sacks D, 1999. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis I80: 564-567.
6. Sundar S, Singh VP, Sharma S, Makharia MK, Murry HW, 1997. Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. J Infect Dis I76: 1117-1119.
7. Thakur CP, Narayan S, Ranjan A, 2004. Epidemiological, clinical and pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India. Indian J Med Res I20: 166-172.
8. Das VN, Ranjan A, Bimal S, Siddique NA, Pandey K, Kumar N, Verma N, Singh VP, Sinha PK, Bhattacharya SK. 2005. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar. Natl Med J India 18: 131-133.
9. Thakur CP, Sinha GP, Pandey AK, Kumar N, Kumar P, Hassan SM, Narain S, Roy RK, 1998. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India justify its continued use as a first-line drug? An observational study of 80 cases. Ann Trop Med Parasitol 92: 561-569.
10. Ahasan HA, Chowdhury MA, Azhar MA, Rafiqueuddin AK, Azad KA, 1996. Deaths in visceral leishmaniasis (kala-azar) during treatment. Med J Malaysia 5I: 29-32.
11. Sindermann H, Engel J, 2006. Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg I00 (Suppl I): S17-S20.
12. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 1739-1746.
13. Sundar S, Murray HW, 2005. Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ 83: 394-395.
14. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK, 2007. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 356: 2571-2581.
15. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW, 2004. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 38: 377-383.
16. WHO, 2005. Report of a WHO Informal Consultation on Liposomal Amphotericin B in the Treatment of Visceral Leishmaniasis. Available at: http://www.who.int/neglected-diseases/resources/AmBisomeReport.pdf. Accessed December 17, 2009.
17. Sundar S, Rai M, 2002. Advances in the treatment of leishmaniasis. Curr Opin Infect Dis I5: 593-598.
18. Rosenthal E, Marty P, 2003. Recent understanding in the treatment of visceral leishmaniasis. J Postgrad Med 49: 61-68.
19. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW, 2001. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 323: 419-422.
20. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R, 2003. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 37: 800-804.
21. Thakur CP, Pandey AK, Sinha GP. Roy S, Behbehani K, Olliaro P, 1996. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomised dose finding study. Trans R Soc Trop Med Hyg 90: 319-322.
22. Thakur CP, 2001. A single dose treatment of kala-azar with AmBisome (amphotericin B lipid complex): a pilot study. Int J Antimicrob Agents 17: 67-70.
23. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R, 2002. Low dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 66: 143-146.
24. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW, 2010. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 362: 504-512.
25. Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J, 2006. Liposomal amphotericin B for the treatment visceral leishmaniasis. Clin Infect Dis 43: 917-924. (Pubitemid 44435523)
26. Collin S, Davidson R, Ritmeijer K, Keus K, Melaku Y, Kipngetich S, Davies C, 2004. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis 38: 612-619.
27. Centres for Disease Control and Prevention, 2009. The SAS Program for the CDC Growth Charts. Available at: http://www.cdc.gov/nccdphp/dnpa/growthcharts/ resources/sas.htm. Accessed April 14, 2009.
28. National Cancer Institute Cancer Therapy Evaluation Program, 2003. Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE) DCTD, NCI, NIH, DHHS. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf. Accessed December 21, 2009.
29. Astellas Pharma US, Inc., 2007. AmBisome (Amphotericin B) Liposome for Injection. Available at: http://www.ambisome.com/index2.php?section= about&page=trials. Accessed March 19, 2009.
30. Schmid C, Nkunku S, Merolle A, Vounatsou P, Burri C, 2004. Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness. Lancet 364: 789-790.
31. Schmid C, Richer M, Bilenge CM, Josenando T, Chappuis F, Manthelot CR, Nangouma A, Doua F, Asumu PN, Simarro PP, Burri C, 2005. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (impamel II). J Infect Dis I9I: 1922-1931.
32. Checchi F, Piola P, Ayikoru H, Thomas F, Legros D, Priotto G, 2007. Nifurtimox plus eflornithine for late-stage sleeping sickness in Uganda: a case series. PLoS Negl Trop Dis 1: e64.
33. Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson AD, 1998. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 76: 25-32.
34. Adler-Moore J, Proffitt RT, 2002. Ambisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 49 (Suppl 1): 21-30.